Brigatinib received approval for the treatment of anaplastic lymphoma kinase-positive metastatic NSCLC patients who had progressive disease while taking crizotinib or who were intolerant to crizotinib (80). This evidence concerns the gene ALK and non-small cell lung carcinoma.